Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer

Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo

(2016) Jun Yan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Anti-breast tumor activity of Eclipta extract in-vitro and in-vivo: novel evidence of endoplasmic reticulum specific localization of Hsp60 during apoptosis

(2015) Rakesh K. Arya et al.   Scientific Reports

Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5

(2015) Xu Di et al.   Oncotarget

Synthesis of novel β-carboline based chalcones with high cytotoxic activity against breast cancer cells

(2014) Shikha S. Chauhan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells

(2014) Dan Wang et al.   BMC CANCER

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice

(2014) Wei Wang et al.   GASTROENTEROLOGY

Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction

(2014) Ana Z. Gonzalez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

(2014) Yujun Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

(2014) Wei Wang et al.   Nature Communications

Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737

(2013) A Maamer-Azzabi et al.   Cell Death & Disease

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay

(2011) A. G. Herman et al.   Cancer Discovery

Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy

(2010) A.S. Azmi et al.   CURRENT CANCER DRUG TARGETS

CXCR3-B Can Mediate Growth-inhibitory Signals in Human Renal Cancer Cells by Down-regulating the Expression of Heme Oxygenase-1

(2010) Dipak Datta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

p53 post-translational modification: deregulated in tumorigenesis

(2010) Chao Dai et al.   TRENDS IN MOLECULAR MEDICINE

Calcineurin Inhibitors Activate the Proto-Oncogene Ras and Promote Protumorigenic Signals in Renal Cancer Cells

(2009) D. Datta et al.   CANCER RESEARCH

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

(2009) Ramzi M Mohammad et al.   Molecular Cancer

Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53

(2008) Jason A. Clement et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans

(2008) K Linke et al.   CELL DEATH AND DIFFERENTIATION

TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5

(2008) Y. Zhang et al.   MOLECULAR CANCER RESEARCH